Differential Actions of Antiparkinson Agents at Multiple Classes of Monoaminergic Receptor. III. Agonist and Antagonist Properties at Serotonin, 5-HT1 and 5-HT2, Receptor Subtypes-Reference-Cited by-同舟云学术

Differential Actions of Antiparkinson Agents at Multiple Classes of Monoaminergic Receptor. III. Agonist and Antagonist Properties at Serotonin, 5-HT1 and 5-HT2, Receptor Subtypes

Published:2002-11-01 Issue:2 Volume:303 Page:815-822
ISSN:0022-3565
Container-title:Journal of Pharmacology and Experimental Therapeutics
language:en
Short-container-title:J Pharmacol Exp Ther

Author:

Newman-Tancredi Adrian,Cussac Didier,Quentric Yann,Touzard Manuelle,Verrièle Laurence,Carpentier Nathalie,Millan Mark J.

Publisher

American Society for Pharmacology & Experimental Therapeutics (ASPET)

Subject

Pharmacology,Molecular Medicine

Reference57 articles.

1. Antagonism of reserpine-induced suppression of spontaneous motor activity by stimulation of 5-HT1A receptors in rats.;Ahlenius;Pharmacol Toxicol,1995

2. Aromatic L-amino acid decarboxylase is present in serotonergic fibers of the striatum of the rat. A double-labeling immunofluorescence study

3. Inverse Agonist Properties of Antipsychotic Agents at Cloned, Human (h) Serotonin (5-HT)1B and h5-HT1D Receptors

4. Agonist-directed signaling of serotonin 5-HT2C receptors: differences between serotonin and lysergic acid diethylamide (LSD).;Backstrom;Neuropsychopharmacology,1999

5. A review of central 5-HT receptors and their function

Cited by 182 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Tips and tricks in tremor treatment;Journal of Neural Transmission;2024-07-24

2. Natural Product-Inspired Dopamine Receptor Ligands;Journal of Medicinal Chemistry;2024-07-22

3. Cabergoline targets multiple pathways to inhibit PRL secretion and increases stromal fibrosis;European Journal of Endocrinology;2024-05-23

4. Comparative Pharmacological Effects of Lisuride and Lysergic Acid Diethylamide Revisited;ACS Pharmacology & Translational Science;2024-02-05

5. Microdosing psychedelics and the risk of cardiac fibrosis and valvulopathy: Comparison to known cardiotoxins;Journal of Psychopharmacology;2024-01-12